Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARDMQ
Aradigm
$0.05
$0.05
$0.02
▼
$0.20
$764KN/A21,923 shsN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.16
$0.16
$0.16
▼
$1.57
$763K4.024,068 shsN/A
ECIA
Encision
$0.01
$0.05
$0.00
▼
$0.39
$217K-8.173,971 shsN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$1.10
-5.2%		$3.56
$1.00
▼
$112.50
$777K0.73795,729 shs89,183 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARDMQ
Aradigm
0.00%0.00%0.00%0.00%0.00%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%0.00%0.00%+13,300.00%
ECIA
Encision
0.00%0.00%-71.67%-65.57%-96.81%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
+12.62%+4.50%-54.51%-85.38%-99.02%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARDMQ
Aradigm
$0.05
$0.05
$0.02
▼
$0.20
$764KN/A21,923 shsN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.16
$0.16
$0.16
▼
$1.57
$763K4.024,068 shsN/A
ECIA
Encision
$0.01
$0.05
$0.00
▼
$0.39
$217K-8.173,971 shsN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
$1.10
-5.2%		$3.56
$1.00
▼
$112.50
$777K0.73795,729 shs89,183 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARDMQ
Aradigm
0.00%0.00%0.00%0.00%0.00%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%0.00%0.00%+13,300.00%
ECIA
Encision
0.00%0.00%-71.67%-65.57%-96.81%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
+12.62%+4.50%-54.51%-85.38%-99.02%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARDMQ
Aradigm
0.00
N/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00
N/AN/AN/A
ECIA
Encision
0.00
N/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ECIA, GCTK, ARDMQ, and ARTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K9.53N/AN/A($2.43) per share-0.07
ECIA
Encision
$5.78M0.04N/AN/A$0.08 per share0.14
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/A$41.93 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARDMQ
Aradigm
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98M-$2.34N/AN/AN/A-8,257.70%N/A-730.22%N/A
ECIA
Encision
-$720K-$0.03N/AN/AN/AN/AN/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
-$19.39M-$137.63N/AN/AN/AN/A-2,135.52%-290.22%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ARDMQ
Aradigm
N/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
ECIA
Encision
N/AN/AN/AN/AN/A
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARDMQ
Aradigm
N/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.10
0.01
ECIA
Encision
0.10
1.74
0.69
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
N/A
0.46
0.46

Institutional Ownership

CompanyInstitutional Ownership
ARDMQ
Aradigm
N/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
ECIA
Encision
8.20%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
10.92%

Insider Ownership

CompanyInsider Ownership
ARDMQ
Aradigm
4.50%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
ECIA
Encision
36.75%
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
ARDMQ
Aradigm
2315.28 millionN/ANot Optionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
104.74 million4.53 millionNot Optionable
ECIA
Encision
3018.88 million11.94 millionNot Optionable
GlucoTrack, Inc. stock logo
GCTK
GlucoTrack
15706,000664,000Not Optionable

Recent News About These Companies

Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/l-kahi-therapeutics-expands-university-211500089.html
Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14
September 30, 2026  |  marketscreener.comM
Lokahi Therapeutics Expands ai2 Pipeline Program through Collaboration with Pepperdine E2B
September 28, 2026  |  marketscreener.comM
Glucotrack Prices $3.1M Public Offering
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3693705/glucotrack-prices-3-1m-public-offering.aspx
Biotech Stocks On The Move - APUS, PFSA, GCTK, ARCT
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3693768/biotech-stocks-on-the-move-apus-pfsa-gctk-arct.aspx
Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/l-kahi-therapeutics-expands-ai2-130000171.html
Lokahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
September 25, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/09/25/10452212.htm
Glucotrack prices $3.1M public offering at $2.04 per share
September 24, 2026  |  streetinsider.comhttps://www.streetinsider.com/Equity+Offerings/Glucotrack+prices+%243.1M+public+offering+at+%242.04+per+share/27099423.html
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/glucotrack-inc-announces-pricing-3-124500880.html
Lokahi Therapeutics and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai-2 Platform Growth and Clinical Development Priorities
September 24, 2026  |  marketscreener.comM
GlucoTrack (GCTK) Stock Soars 118% on Lōkahi’s Debut Partnership Agreement
September 24, 2026  |  blockonomi.comhttps://blockonomi.com/glucotrack-gctk-stock-soars-118-on-lokahis-debut-partnership-agreement/
GlucoTrack (GCTK) Stock Jumps 118% After Lōkahi Signs First Partnership Deal
September 24, 2026  |  coincentral.comC
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
September 24, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61964676/why-glucotrack-shares-are-trading-higher-by-around-118-here-are-20-stocks-moving-premarket?utm_source=snapi
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
September 23, 2026  |  rutlandherald.comR
GCTK Share News Today
September 19, 2026  |  uk.investing.comhttps://uk.investing.com/equities/integrity-news
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
September 18, 2026  |  marketscreener.comM
Glucotrack Secures $11.5M Financing To Advance Diabetes Technology; Stock Down
September 11, 2026  |  rttnews.comhttps://www.rttnews.com/3690405/glucotrack-secures-11-5m-financing-to-advance-diabetes-technology-stock-down.aspx
Glucotrack Announces $11.5 Million Financing
September 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/glucotrack-announces-11-5-million-120000340.html
Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions
September 8, 2026  |  rutlandherald.comR
Lokahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
September 2, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/09/02/10439349.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Laptop displaying a cash flow analysis dashboard with bar charts, beside a printed cash flow statement on an office desk.
3 Nimble Free Cash Flow Names With Light Assets
By Nathan Reiff | September 18, 2026
Multi-monitor trading desk displaying candlestick stock price charts, market data tables, and a city skyline at dusk.
4 Stocks That Could Split Next—and Why Investors Are Watching
By Thomas Hughes | September 30, 2026
Genius Sports logo displayed over a soccer stadium field with stands and floodlights in the background.
JPMorgan Bets on Genius Sports as the Market Loses Patience
By Chris Markoch | October 1, 2026

Aradigm OTCMKTS:ARDMQ

$0.05 0.00 (0.00%)
As of 06/30/2020

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Arch Therapeutics stock logo

Arch Therapeutics OTCMKTS:ARTH

$0.16 0.00 (0.00%)
As of 10/12/2026

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Encision OTCMKTS:ECIA

$0.01 0.00 (0.00%)
As of 10/12/2026

Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.

GlucoTrack stock logo

GlucoTrack NASDAQ:GCTK

$1.10 -0.06 (-5.17%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas